Document is current
Any future updates will be listed below
-
Authors
Kaidar-Person, Orit https://orcid.org/0000-0003-4023-1869
Tramm, Trine
Kuehn, Thorsten
Gentilini, Oreste
Prat, Aleix
Montay-Gruel, Pierre
Meattini, Icro
Poortmans, Philip
- License Information
-
More Information
Article History
Received: 18 May 2023
Accepted: 12 October 2023
First Online: 3 November 2023
Declarations
:
: Dr. Trine Tramm – none related to the review, received fees for participating in advisory board and for giving lectures for Pfizer. Aleix Prat—Dr. Prat, are equity stockholders of Reveal Genomics; Dr. Prat reports grants from Reveal Genomics, during the conduct of the study; other from Reveal Genomics, personal fees from Roche, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi-Sankyo, grants and personal fees from Novartis, personal fees from Foundation Medicine, personal fees from Oncolytics Biotech, outside the submitted work; In addition, Dr. Prat has a patent HER2DX licensed to Reveal Genomics, and a patent WO 2018/103834 licensed to Reveal Genomics. Icro Meattini—declares occasional small fees received for advisory board supported by Eli Lilly, Novartis, Gilead, Seagen, Pfizer. The authors have no relevant financial or non-financial interests to disclose: OKP, TK, PHP, GO, PGM.
: As a review paper, the work does not need ethics approval, nor patient inform consent.
